Table 1.
Patients' clinical and biological characteristics.
| Patients' characteristic | B-R 111 patients | Chl-R 81 patients |
|---|---|---|
| Median age at treatment | 69 years (range: 65–81) | 75 years (range: 65–85) |
| Age 65–75 | 90 (81.0%) | 46 (56.8%) |
| Age >75 | 21 (19.0%) | 35 (43.2%) |
| Male/female | 65/46 | 50/31 |
| Cumulative Illness Rating Scale score >6 | 9 patients (8.1%) | 20 patients (24.7%) |
| Eastern Cooperative Oncology Group (ECOG) score 0 | 81 (73.0%) | 51 (63.0%) |
| ECOG score >1 | 30 (27.0%) | 30 (37.0%) |
| Lymphocytes count (range) | 59.5 × 109/L (3.0–240.0) | 64.0 × 109/L (3.0–240.0) |
| Hemoglobin levels (range) | 12.8 g/L (5.8–16.6) | 12 g/L (7.7–16.6) |
| Platelet count (range) | 164 × 109/L (23–472) | 142 × 109/L (41–362) |
| Binet A | 33 (29.7%) | 42 (51.8%) |
| Binet B | 67 (60.4%) | 33 (40.7%) |
| Binet C | 11 (9.9%) | 6 (7.4%) |
| Fluorescence in situ hybridization analysis | 88/111 patients | 75/81 patients |
| Normal karyotype | 35 (39.8%) | 20 (26.7%) |
| 13q deletion | 25 (28.4%) | 33 (44.0%) |
| +12 | 15 (17.0%) | 15 (20.0%) |
| 11q deletion | 9 (10.2%) | 7 (9.3%) |
| 17p deletion | 4 (4.5%) | - |
| Immunoglobulin heavy chain gene | 61/111 | 51/81 |
| Unmutated | 42 (68.9%) | 29 (56.9%) |
| Mutated | 19 (31.1%) | 22 (43.1%) |
| Subgroup | 55/111 | 52/81 |
| Low-risk group | 18 (32.7%) | 20 (38.5%) |
| Intermediate-risk group | 37 (67.3%) | 32 (61.5%) |
| B and Chl dose/patient (range) | 1,680 mg (200–2,700) | 600 mg (210–980) |
| Median dose for cycle (range) | 300 mg (120–450) | 90 mg (60–130) |
| R dose/patient (range) | 4,600 mg (1,270–7,750) | 3,900 mg (600–7,350) |
| Median dose for cycle (range) | 775 mg (600–1,000) | 666 mg (350–1,000) |